Opinion

Video

Patient Profile 3: A 67-Year-Old Male with Recurrent Prostate Cancer

Author(s):

Brian Helfand, MD, PhD,Brian Chapin, MD

Drs Helfand, Chapin, and Collins, review the case of 67-year-old man treated with recurring prostate cancer.

Current Time 0:00
Duration 9:24
Loaded: 1.75%
Stream Type LIVE
Remaining Time 9:24
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected
    Related Videos
    Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
    Strategies to bridge gender disparities in AAS and citations in the oncology literature
    Stacy Loeb, MD, MSc, PhD (Hon), answers a question during a Zoom video interview
    Stacy Loeb, MD, MSc, PhD (Hon), discusses the nuances of prostate cancer screening
    1 expert in this video
    Selecting Between Receptor Pathway Inhibitors for mHSPC
    1 expert in this video
    The Use of Ultra-Low PSA in Specific Patient Profiles
    Fred Saad, MD, FRCS, discusses clinical impact of darolutamide approval in mCSPC
    Fred Saad, MD, FRCS, discusses clinical impact of darolutamide approval in mCSPC
    Ryan Hankins, MD, on rectal spacer utilization and erectile dysfunction
    Ryan Hankins, MD, on rectal spacer utilization and erectile dysfunction
    Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer
    Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer
    Fred Saad, MD, FRCS, reacts to FDA approval of darolutamide in mCSPC
    Fred Saad, MD, FRCS, reacts to FDA approval of darolutamide in mCSPC
    1 expert in this video
    Using Ultrasensitive PSA Assays in Routine Practice
    1 expert in this video
    Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point
    Related Content
    AI-based tool aims to optimize MRI use in prostate cancer diagnosis
    June 12th 2025

    AI-based tool aims to optimize MRI use in prostate cancer diagnosis

    Madhur Nayan, MD, PhD
    "I'm excited to see how these models are going to continue to be developed and applied in clinical practice, because precision medicine is here, and I’m looking forward to it," says Madhur Nayan, MD, PhD.
    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
    April 27th 2025

    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

    Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
    Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
    Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC
    June 9th 2025

    Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC

    Hannah Clarke
    In preclinical studies, ACE-232 demonstrated superior potency, efficacy, and pharmacokinetic properties compared with other CYP11A1 inhibitors.
    Dr. Murphy on increasing diversity in cancer clinical trials
    February 29th 2024

    Dr. Murphy on increasing diversity in cancer clinical trials

    Urology Times staff
    In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
    Amy L. Shaver, PhD, PharmD, MPH
    June 5th 2025

    GLP-1 agonist use is rising in men with prostate cancer

    Benjamin P. Saylor
    In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024.
    Doctor giving a consultation to a patient and explaining medical informations and diagnosis | Image Credit: © Pcess609 - stock.adobe.com
    June 4th 2025

    ARANOTE: Darolutamide improves HRQoL in mHSPC

    Benjamin P. Saylor
    Treatment with darolutamide was found to extend median time to deterioration of FACT-P total score by 5.1 months vs placebo
    © 2025 MJH Life Sciences

    All rights reserved.